
-- Initiation of Phase III study for lead product COL-003 in patients with chronic low back pain
-- Funding to enable development through NDA filing
CUMBERLAND, R.I.--(BUSINESS WIRE)--Collegium Pharmaceutical, Inc., a specialty pharmaceutical company focused on the development of innovative treatments for chronic pain, announced today that it has raised $22.5 million in a Series B financing round led by Longitude Capital and Skyline Ventures. Series A investors Frazier Ventures...
More »
BOSTON--(BUSINESS WIRE)--Charles River Associates (NASDAQ: CRAI), a worldwide leader in providing economic, financial, and management consulting services, today announced that its Board of Directors has authorized an expanded share repurchase program of up to $4.45 million of its common stock, in addition to its currently existing share repurchase program. In August 2011, the Company announced that its Board of Directors authorized a share repurchase program of up to $7.5 million...
More »